BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03

On June 12, 2020, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation, as amended (the “Charter Amendment”) to increase the number of authorized shares of the Company’s common stock from 10,000,000 shares to 15,000,000 shares. As described below under Item 5.07, the Charter Amendment was approved by the Company’s stockholders at the 2020 Annual Meeting (as defined below). The Charter Amendment is filed herewith as Exhibit 3.1 and is incorporated by reference.

The 2020 annual meeting of stockholders of the Company (the “2020 Annual Meeting”) was held on June 12, 2020 via remote communication. At the 2020 Annual Meeting, the holders of 6,722,687 shares of the Company’s common stock were represented in person or by proxy, thereby constituting a quorum.

Set forth below are the final voting results for each of the matters submitted to a vote of the stockholders of the Company at the 2020 Annual Meeting.

Proposal 1. The stockholders of the Company elected Jennifer Chao, Mark Wegman, and Toby Wegman to the Board of Directors of the Company (the “Board”) to serve as Class III directors until the 2023 annual meeting of stockholders or until he or she resigns, is removed, or otherwise leaves office. The votes were cast as follows:

(d) Exhibits

Story continues below


BIOSPECIFICS TECHNOLOGIES CORP Exhibit
EX-3.1 2 d944358dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BIOSPECIFICS TECHNOLOGIES CORP. BioSpecifics Technologies Corp. (the “Corporation”),…
To view the full exhibit click here

About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)

BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.

An ad to help with our costs